: Sunday, May 23, 2021, 4:20 PM IST
Adar Poonawalla is the only official spokesperson: Serum Institute disassociates itself from its executive s remarks on COVID vaccination drive
Adar Poonawalla is the only official spokesperson: Serum Institute disassociates itself from its executive s remarks on COVID vaccination drive
New Delhi: The Serum Institute has disassociated itself from its executive director s statement that the government began the COVID-19 vaccination of multiple age groups without taking into consideration the available stock, stating that this is not the view of the company .
In a letter to the Union Health Ministry on May 22, Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Pune-based Serum Institute of India (SII), clarified that the statement by its executive director Suresh Jadav at a recent event is not the view of the company, sources said.
: Thursday, May 13, 2021, 7:07 PM IST Very good move : Serum Institute CEO Adar Poonawalla after Centre extends gap between two doses of Covishield to 12-16 weeks
Serum Institute CEO Adar Poonawalla
The Union Health Ministry on Thursday accepted the recommendation of the COVID working group to extend the gap between the first and second doses of the Pune-based Serum Institute of India s COVID-19 vaccine Covishield vaccine to 12-16 weeks. The present gap between the two doses of the vaccine is 6-8 weeks.
Union Health Minister Dr. Harsh Vardhan took to Twitter regarding the decision made by the ministry. He tweeted: Gap between 2 doses of #CovishieldVaccine has been increased to 12-16 weeks from 6-8 weeks currently. Decision has been taken based on recommendations given by COVID working group after analysing emerging evidence.
Serum Institute CEO Adar Poonawalla plans vaccine production outside India: Report
Twitter/ @adarpoonawalla
With the surge in coronavirus cases and deaths in India, Pune-based Serum Institute of India (SII) is struggling to meet supplies. CEO Adar Poonawalla told Times of India on Friday that the firm is planning to begin vaccine production outside India. Poonawalla said, âthere s going to be an announcement in the next few daysâ.
The SII, which is India s largest vaccine manufacturer and the worldâs by volume, manufactures the AstraZeneca COVID-19 vaccine jointly developed with Oxford University. It is sold in India under the name Covishield.
Centre asks Serum Institute, Bharat biotech to lower their COVID-19 vaccine prices: Report
(Photo by AFP)
The Central government on Monday has asked the Serum Institute of India (SII) and Bharat Biotech to lower the prices of their COVID-19 vaccines ahead of the third phase of the vaccination drive from May 1 where all citizens above the age of 18 will be administered the vaccine, official sources told news agency PTI.
Govt asks Serum Institute, Bharat Biotech to lower price of COVID vaccines as India gears up to inoculate all aged above 18: Official sources Press Trust of India (@PTI News) April 26, 2021
Reportedly, the issue of vaccine pricing was discussed at a meeting chaired by Cabinet Secretary Rajiv Gauba. And now the two manufacturing companies are expected to come up with revised pricing for their vaccines.
After strong criticism, govt asks Serum Institute, Bharat Biotech to lower price of COVID-19 vaccines
AFP Photo
NEW DELHI: Strong criticism of different prices for the same vaccines produced by the same two manufacturers led the Centre on Monday to ask them to reduce their prices. The development has come just five days ahead of the mass vaccination drive covering all adults who are 18 or 18+.
There is, however, no certainty that the manufacturers will agree to sell Covishield and Covaxin vaccines to the states and the private hospitals at Rs 150 per dose, the rate fixed for supplies to the Centre, as both Serum Institute and Bharat Biotech claim their production cost is much higher at Rs 200 per dose.